Formulary positioning has become the single most decisive factor in pharmaceutical market success. In modern healthcare systems—especially in the United States—payers, pharmacy benefit managers (PBMs), and health systems control access, not physicians alone.

For pharmaceutical companies and sales teams, formulary placement determines:

Whether a drug gets prescribed
Whether patients can afford it
Whether revenue projections materialize

This article provides a comprehensive, evidence-based playbook on how to position a drug on formularies—grounded in payer behavior, regulatory frameworks, and real-world commercial strategy.

What Is a Formulary—and Why It Controls Everything

A formulary is a structured list of medications that a health plan covers, along with rules governing access, cost-sharing, and utilization management.

It functions as:

A coverage blueprint
A cost-control mechanism
A behavioral tool influencing prescribing patterns

Modern formularies operate through tiering systems:

Tier 1: Low-cost generics
Tier 2: Preferred brands
Tier 3+: Non-preferred or specialty drugs

PBMs play a dominant role in designing and managing formularies. They negotiate with manufacturers and aggregate purchasing power across multiple plans, effectively centralizing decision-making.

Key data point:

Over 90% of prescriptions in the U.S. are generic, reflecting formulary-driven cost prioritization.

The Economics of Formulary Placement

Formulary decisions rarely hinge on clinical efficacy alone. They reflect a balance of:

Clinical value
Economic impact
Competitive landscape
Contracting terms

Net Cost Is the Real Decision Driver

Payers evaluate drugs using a simple but powerful formula:

Net Cost = List Price – Rebates and Discounts

A higher-priced drug can still secure preferred status if it offers larger rebates or lower total cost of care.

Competitive Intensity Shapes Positioning

According to analysis from Deloitte:

Drugs with strong differentiation and low competition gain favorable placement
Crowded therapeutic classes require aggressive pricing and evidence strategies

The Core Drivers of Formulary Positioning

1. Clinical Differentiation

Payers prioritize therapies that demonstrate:

Superior efficacy
Better safety profiles
Improved adherence

Even small differences matter when translated into outcomes like reduced hospitalizations.

2. Health Economics and Outcomes Research (HEOR)

HEOR has become central to formulary success.

Payers act as “commercial gatekeepers” evaluating value evidence
Economic models and outcomes data directly influence coverage decisions

What Payers Want to See

Cost-effectiveness (cost per QALY)
Budget impact models
Total cost of care reductions

3. Real-World Evidence (RWE)

RWE increasingly determines post-launch positioning.

80% of U.S. payers use RWE in decision-making
65% say RWE has changed formulary status post-launch

This shift reflects growing skepticism toward clinical trial data alone.

4. Pricing and Rebates

Rebates remain one of the most powerful levers.

Manufacturers offer financial concessions
PBMs reward higher rebates with better placement

This creates a “rebate-driven formulary ecosystem” where net price outweighs list price.

5. Utilization Management Compatibility

Drugs that fit into payer control frameworks perform better.

Examples:

Step therapy alignment
Prior authorization criteria
Clear patient segmentation

The Role of PBMs and P&T Committees

Pharmacy Benefit Managers (PBMs)

PBMs:

Negotiate drug pricing
Design formularies
Control access across millions of patients

Their scale gives them significant leverage over manufacturers.

Pharmacy & Therapeutics (P&T) Committees

P&T committees evaluate:

Clinical evidence
Economic models
Comparative effectiveness

They decide:

Tier placement
Restrictions (PA, step therapy)
Preferred vs non-preferred status

A Step-by-Step Strategy to Win Formulary Placement

Step 1: Start Before Launch

Early engagement is critical.

Initiate discussions with payers 12–24 months pre-launch
Align clinical trial endpoints with payer expectations
Build preliminary HEOR models

Insight: Late engagement drastically reduces leverage.

Step 2: Build a Compelling Value Story

Your drug must answer:

Why should a payer cover this?
Why should it be preferred?

Strong Value Narratives Include

Reduced hospitalizations
Improved adherence
Lower long-term costs

Example: A migraine drug achieved favorable placement by demonstrating a 30% reduction in ER visits, proving economic value.

Step 3: Develop Robust HEOR Evidence

Invest in:

Cost-effectiveness analyses
Budget impact models
Comparative effectiveness studies

HEOR must translate clinical outcomes into financial terms.

Step 4: Generate Real-World Evidence Early

Do not wait post-launch.

Use early access programs
Leverage registries and claims data
Publish outcomes quickly

RWE strengthens payer confidence and supports re-positioning.

Step 5: Design Competitive Contracting Strategies

Contracting determines access.

Key Levers

Rebates
Volume-based discounts
Value-based agreements

Outcome-based contracts align payment with performance, increasing payer trust.

Step 6: Optimize Pricing Strategy

Pricing must reflect:

Competitive landscape
Payer willingness to pay
Clinical differentiation

Overpricing without evidence leads to:

Non-preferred status
High patient cost-sharing
Low uptake

Step 7: Align With Treatment Pathways

Position your drug within:

Clinical guidelines
Standard-of-care pathways

Drugs aligned with guidelines face fewer restrictions.

Step 8: Support Providers With Access Tools

Even with formulary placement, barriers remain.

Provide:

Prior authorization support
Copay assistance
Patient onboarding programs

These tools improve real-world utilization.

Advanced Strategies for Competitive Markets

1. Indication-Based Positioning

Target subpopulations where your drug shows strongest value.

Improves cost-effectiveness
Strengthens payer negotiations

2. Lifecycle Management

Expand indications over time.

Move from niche to broader populations
Improve formulary positioning incrementally

3. Differentiation Beyond Efficacy

In crowded markets, emphasize:

Dosing convenience
Adherence benefits
Safety advantages

4. Value-Based Contracts

Tie reimbursement to outcomes:

Reduced hospitalizations
Disease remission rates

These contracts reduce payer risk.

Common Reasons Drugs Fail to Achieve Favorable Placement

1. Weak Economic Evidence

Clinical success alone does not secure access.

2. Late Market Access Engagement

Payers expect early collaboration.

3. Misaligned Pricing

High price without justification leads to exclusion or restrictions.

4. Lack of Real-World Data

Payers increasingly distrust trial-only evidence.

5. Poor Competitive Positioning

Failure to differentiate within a crowded class results in non-preferred status.

The Sales Team’s Role in Formulary Success

Formulary positioning is not just a market access function. Sales teams play a critical role.

1. Field Intelligence

Sales reps gather insights on:

Payer restrictions
Physician challenges
Regional access variations

2. Evidence Communication

Reps translate HEOR into:

Clinical relevance
Economic value
Patient impact

3. Provider Support

Help physicians navigate:

Prior authorizations
Step therapy requirements
Appeals processes

4. Feedback Loop

Sales teams inform:

HEOR strategy
Market access negotiations
Lifecycle planning

Regulatory Considerations

United States

Formulary decisions must comply with:

Medicare Part D requirements (e.g., coverage of at least two drugs per class)
Transparency rules
Anti-kickback regulations

Global Context

Countries with centralized HTA systems (e.g., UK, EU) require:

Cost-effectiveness thresholds
National reimbursement approval

These systems make HEOR even more critical.

The Future of Formulary Positioning

1. Increased Use of Real-World Evidence

RWE will become a baseline requirement, not a differentiator.

2. AI-Driven Payer Decision-Making

Predictive analytics will:

Optimize formularies
Identify high-value therapies

3. Expansion of Value-Based Pricing

Contracts tied to outcomes will grow.

4. Greater Transparency and Regulation

Governments will scrutinize:

Rebate structures
PBM practices
Drug pricing

Key Takeaways

Formulary placement determines commercial success
Net cost—not list price—drives decisions
HEOR and RWE are essential for access
Early payer engagement is critical
Sales teams must understand and communicate value

Conclusion

Formulary positioning has evolved into a sophisticated negotiation between pharmaceutical manufacturers and payers. Clinical efficacy opens the door—but economic value, real-world outcomes, and strategic contracting determine whether a drug walks through it.

Companies that integrate HEOR, pricing strategy, and payer engagement into a unified approach will secure access and drive growth. Those that fail to adapt will find their products sidelined—regardless of clinical merit.

References

HMPI – Pharmacy Benefit Managers and the U.S. Pharmaceutical Market
https://hmpi.org/2024/04/12/pharmacy-benefit-managers-and-the-us-pharmaceutical-market/
Deloitte Insights – Pharmaceutical Pricing and Market Access
https://www.deloitte.com/us/en/insights/industry/life-sciences/pharmaceutical-pricing-market-access.html
Pharmacy Standards – Formulary Strategy and Payer Collaboration
https://pharmacystandards.org/casp/section-14-4-formulary-strategy-and-payer-collaboration/
Petauri Evidence – U.S. Payer Survey on RWE
https://www.linkedin.com/posts/petauri-evidence_pharma-marketaccess-evidencestrategy-activity-7350887451558572032-XAM9
US Pharma Marketing – Formulary Strategy Insights
https://uspharmamarketing.com/formularies-favours-and-pharma-sales-the-real-prescription-for-big-market-success/
Fierce Pharma – HEOR Impact on Formularies
https://www.fiercepharma.com/marketing/health-economics-and-outcomes-research-heor-continues-to-be-most-important-among-0